New Chemical Modifications Revolutionize siRNA Drugs by Minimizing Side Effects.
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that specifically silence genes associated with genetic diseases by targeting messenger RNA (mRNA) and preventing the translation of disease-causing proteins. Despite their promise, siRNA drugs face significant challenges, particularly due to off-target effects, where siRNAs interact with unintended mRNA sequences, leading to harmful side effects. These off-target effects pose a major barrier to the therapeutic application of siRNAs, necessitating advanced molecular modifications to enhance their specificity and safety.
Challenges of siRNA: Off-Target Effects
siRNAs consist of two strands: a guide strand and a passenger strand. The guide strand forms a complex with proteins in the RNA-induced silencing complex (RISC) within cells, and one key protein, Argonaute2 (Ago2), cleaves mRNA sequences complementary to the guide strand. This gene-silencing effect is crucial in treating various genetic diseases. However, the therapeutic potential of siRNAs is often hindered by unintended interactions, particularly involving the seed region—a critical seven-nucleotide sequence within the guide strand that is essential for target recognition.
The seed region can also form base pairs with non-target mRNAs, resulting in off-target effects that can disrupt essential cellular processes, impair immune responses, and cause other adverse effects. This non-specific interaction significantly limits the safety and efficacy of siRNA-based therapies.
Formamide Modifications: A Novel Solution to Off-Target Effects
To address these off-target effects, researchers have explored various chemical modifications of siRNAs, focusing on altering the seed region to reduce its binding affinity for non-target mRNAs. In a recent study published in Nucleic Acids Research, researchers from Nagoya University synthesized 2′-formamidonucleoside phosphoramidite derivatives and incorporated them into siRNA strands. The introduction of formamide groups into the seed region significantly suppressed off-target effects while preserving on-target gene-silencing activity.
The study synthesized formamido derivatives of the four nucleosides—adenine, guanine, cytosine, and uracil—through a series of chemical reactions. These derivatives were then incorporated into double-stranded RNA, resulting in a slight reduction in the thermodynamic stability of the RNA duplex. However, X-ray crystallography and circular dichroism (CD) spectroscopy confirmed that the RNA maintained its natural A-form structure, crucial for maintaining its biological function.
Mechanism of Action of Formamide Modifications
The formamide modifications work by interfering with hydrogen bonding between complementary bases in the mRNA, destabilizing the helical structure and preventing the seed region of the siRNA from binding to non-target mRNAs. This selective destabilization effectively suppresses off-target interactions without compromising the intended gene silencing.
The study found that introducing the 2′-formamidonucleoside derivative specifically at the 2nd position in the guide strand of the siRNA led to a slight decrease in on-target RNA interference (RNAi) activity. However, incorporating these modifications at other positions within the seed region allowed significant suppression of off-target effects while maintaining robust on-target activity. This modification strategy proved more efficient than other existing chemical modifications, such as 2′-O-methyl (2′-OMe) and locked nucleic acids (LNA), which often require multiple alterations and can reduce on-target efficacy.
Experimental Insights and Efficacy
The experimental data demonstrated that siRNAs modified with 2′-formamidonucleosides exhibited substantial suppression of seed-based off-target effects. The study confirmed that these modifications do not induce major conformational changes, as the overall A-form structure of the RNA was preserved, ensuring that the siRNA retains its therapeutic efficacy against intended mRNA targets. This is a critical advancement over previous modification strategies that could inadvertently alter the RNA’s secondary structure, compromising its function.
Additionally, the modifications were found to be effective with minimal changes to the siRNA sequence, enhancing the flexibility and design of siRNA drugs. Unlike other strategies requiring extensive sequence alterations, the introduction of a single formamide modification could achieve the desired reduction in off-target effects, making it a highly efficient approach for clinical application.
Applications and Future Prospects
The chemically modified siRNAs developed in this study hold significant potential for treating various genetic disorders with minimized side effects. Potential applications include siRNA therapies for hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, primary hypercholesterolemia, and mixed dyslipidemia. These findings highlight the importance of innovative chemical modifications in enhancing the safety and efficacy of siRNA-based therapeutics.
The research conducted by Professor Hiroshi Abe and his team marks a pivotal step forward in overcoming one of the most critical barriers in siRNA drug development. By focusing on targeted modifications that selectively suppress off-target effects, this approach offers a promising path to safer and more effective genetic therapies.
Conclusion
The development of 2′-formamidonucleoside modifications represents a significant breakthrough in siRNA technology, providing a robust solution to the off-target effects that have long limited the clinical use of these drugs. By selectively destabilizing interactions with non-target mRNAs while preserving on-target efficacy, these modifications enhance the therapeutic potential of siRNA drugs. This approach not only improves the safety profile of siRNA therapeutics but also opens new avenues for their application in personalized medicine.
Continued research into chemical modifications and their impact on siRNA behavior will be essential to fully realize the potential of siRNA drugs in treating genetic diseases. The innovative use of 2′-formamidonucleoside derivatives highlights the critical role of chemical biology in refining RNA-based therapies and advancing the field of genetic medicine.
More information: Kohei Nomura et al, Synthesis of 2′-formamidonucleoside phosphoramidites for suppressing the seed-based off-target effects of siRNAs, Nucleic Acids Research (2024). DOI: 10.1093/nar/gkae741
English (United States) ·